10-Q: Pulmonx Reports Q1 2026 Results, Revenue Declines

Pulmonx Corporation reported a decrease in revenue for the first quarter of 2026 compared to the prior year, primarily due to a lack of sales in China.

Summary

• Pulmonx Corporation reported revenue of $20.6 million for the three months ended March 31, 2026, a decrease of 8.7% from $22.5 million in the same period of 2025.
• The company experienced a net loss of $13.7 million for the quarter, a slight improvement from a net loss of $14.4 million in the first quarter of 2025.
• Cost of goods sold decreased by 26.7% to $4.5 million, leading to an improved gross margin of 77.9% compared to 72.5% in the prior year.
• Selling, general, and administrative expenses decreased by 7.8% to $24.1 million, primarily due to reduced advertising, marketing, and travel expenses.
• As of March 31, 2026, the company had $61.6 million in cash and cash equivalents and $37.3 million in outstanding debt.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to the year-over-year revenue decline and continued net losses, despite some operational improvements in gross margin and expense control.

Positives

• Gross margin improved to 77.9% from 72.5% in the prior year's comparable quarter, driven by a favorable geographic sales mix and reduced cost of goods sold.
• Operating expenses were reduced by 6.2% to $29.0 million, with a notable decrease in selling, general, and administrative expenses.
• Net loss decreased by 5.5% to $13.7 million, indicating a slight improvement in operational efficiency.
• The company repaid its CIBC Loan in full in March 2026, reducing its debt obligations.

Negatives

• Revenue decreased by 8.7% to $20.6 million, with declines in both U.S. and international markets.
• The decrease in revenue was attributed to a lack of sales into China pending the renewal of a registration certificate.
• Interest income decreased significantly by 59.5% to $0.4 million due to a lower balance of cash and cash equivalents.
• Interest expense increased by 25.0% to $1.0 million, primarily due to higher interest rates on the new Perceptive Loan.

Risks

• The company has a history of significant net losses and expects to continue incurring losses, with an accumulated deficit of $535.2 million as of March 31, 2026.
• Reliance on a single product, the Zephyr Valve, for the majority of revenue, with limited indications for use.
• Dependence on hospital, physician, and patient adoption of the Zephyr Valve, with potential limitations due to complications like pneumothorax.
• Uncertainty regarding third-party reimbursement and potential for patients to incur significant out-of-pocket costs.
• Manufacturing risks and reliance on single-source suppliers for critical components.
• Potential for IT system compromises and data breaches, impacting operations and reputation.
• The company expects to require substantial additional capital through future equity and debt financings.
• The company's ability to manage growth and maintain compliance with extensive government regulations in the medical device industry.
• Potential for intellectual property litigation and infringement claims.
• The market for severe emphysema treatments may be smaller than estimated, and declining smoking rates could impact the patient pool.

Future Outlook

The company expects to continue incurring net losses for the next several years and anticipates requiring substantial additional funding through future equity and debt financings. Management believes current cash and cash equivalents are sufficient to fund operations for at least the next 12 months.

Management Comments

• Management believes that the Company's existing cash and cash equivalents will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of our condensed consolidated financial statements.
• We expect to continue to incur net losses for the next several years and we expect to require substantial additional funding, which may include future equity and debt financings.

Industry Context

StockSavvy.ai notes that Pulmonx operates in the competitive medical technology sector, specifically focusing on minimally invasive treatments for severe emphysema. The company's performance is closely tied to market adoption, reimbursement policies, and ongoing innovation in respiratory care.

Comparison to Industry Standards

• Pulmonx's gross margin of 77.9% is strong, but the company's overall revenue decline and continued net losses are areas of concern within the medical device industry, where profitability is often a key indicator of sustained success.
• Competitors like Olympus (Spiration Valve System) and Broncus Medical (InterVapor System) also operate in the lung volume reduction market, indicating a competitive landscape where differentiation through clinical outcomes and cost-effectiveness is crucial.

Management Changes

Legal Proceedings

• The company settled a civil investigative demand (CID) from the U.S. Department of Justice (US DOJ) related to an investigation under the False Claims Act concerning sales and marketing of Zephyr Valves. The Qui Tam Action was dismissed on December 22, 2025.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional capital through equity offerings.
• Creditors and lenders will be impacted by the company's debt levels and its ability to service its debt obligations.
• Employees may be affected by the company's financial performance and its need for future capital raises.
• Hospitals and physicians may be impacted by the company's sales performance and the adoption rate of its products.

Next Steps

• Await renewal of registration certificate for sales in China.
• Continue to invest in sales and marketing to drive adoption of Zephyr Valve.
• Continue research and development for next-generation products and expanded indications.
• Manage cash flow and pursue additional financing as needed.

Key Dates

Recommendation

While Pulmonx shows some operational improvements like increased gross margin and reduced operating expenses, the year-over-year revenue decline and continued net losses are significant concerns. The company's reliance on future financing and the competitive landscape in the medical device industry warrant a cautious approach. A 'hold' recommendation reflects the balance between potential future growth and current financial challenges.

Keywords

Pulmonx, 10-Q, SEC Filing, Medical Device, Emphysema Treatment, Zephyr Valve, Financial Results, Revenue, Net Loss, Gross Margin, Operating Expenses, Debt Financing, Perceptive Loan, CIBC Loan, Stock-Based Compensation